Javascript must be enabled to continue!
Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: Diffusion‐weighted 3 tesla MR imaging
View through CrossRef
AbstractPurpose:To evaluate the efficacy of diffusion‐weighted imaging (DWI) on 3 Tesla (T) MR imaging to predict the tumor response to neoadjuvant chemoradiation therapy (CRT) in patients with locally advanced rectal cancer.Materials and Methods:Thirty‐five patients who underwent neoadjuvant CRT and subsequent surgical resection were included. Tumor volume was measured on T2‐weighted MR images before and after neoadjuvant CRT and the percentage of tumor volume reduction was calculated. The apparent diffusion coefficient (ADC) value was measured on the DWI before and after neoadjuvant CRT, and the change of ADC (Δ ADC) was calculated. The histopathologic response was categorized either as a responder to CRT or as a nonresponder. The relationship between the ADC parameters and the percentage of tumor volume reduction or histopathologic response was then evaluated.Results:There was a significant correlation between tumor volume reduction and pre‐CRT ADC and Δ ADC, respectively (r = −0.352, r = 0.615). Pre‐CRT ADC of the histopathologic responders was significantly lower than that of the histopathologic nonresponders (P = 0.034). Δ ADC of the histopathologic responders was significantly higher than that of the histopathologic nonresponders (P < 0.005).Conclusion:DWI on 3T MR imaging may be a promising technique for helping to predict and monitor the treatment response to neoadjuvant CRT in patients with locally advanced rectal cancer. J. Magn. Reson. Imaging 2012;35:110‐116. © 2011 Wiley Periodicals, Inc.
Title: Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: Diffusion‐weighted 3 tesla MR imaging
Description:
AbstractPurpose:To evaluate the efficacy of diffusion‐weighted imaging (DWI) on 3 Tesla (T) MR imaging to predict the tumor response to neoadjuvant chemoradiation therapy (CRT) in patients with locally advanced rectal cancer.
Materials and Methods:Thirty‐five patients who underwent neoadjuvant CRT and subsequent surgical resection were included.
Tumor volume was measured on T2‐weighted MR images before and after neoadjuvant CRT and the percentage of tumor volume reduction was calculated.
The apparent diffusion coefficient (ADC) value was measured on the DWI before and after neoadjuvant CRT, and the change of ADC (Δ ADC) was calculated.
The histopathologic response was categorized either as a responder to CRT or as a nonresponder.
The relationship between the ADC parameters and the percentage of tumor volume reduction or histopathologic response was then evaluated.
Results:There was a significant correlation between tumor volume reduction and pre‐CRT ADC and Δ ADC, respectively (r = −0.
352, r = 0.
615).
Pre‐CRT ADC of the histopathologic responders was significantly lower than that of the histopathologic nonresponders (P = 0.
034).
Δ ADC of the histopathologic responders was significantly higher than that of the histopathologic nonresponders (P < 0.
005).
Conclusion:DWI on 3T MR imaging may be a promising technique for helping to predict and monitor the treatment response to neoadjuvant CRT in patients with locally advanced rectal cancer.
J.
Magn.
Reson.
Imaging 2012;35:110‐116.
© 2011 Wiley Periodicals, Inc.
Related Results
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Abstract PS05-08: Restriction Spectrum Imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer
Abstract PS05-08: Restriction Spectrum Imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer
Abstract
Introduction:
Dynamic contrast-enhanced MRI (DCE) is currently used to evaluate neoadjuvant therapy response of breast cancer (1). However, D...
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Objectives:
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non–small cell lung cancer (NSCLC).
...
Pathological Response Assessment following Long Course Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Single Institutional Cohort Study
Pathological Response Assessment following Long Course Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Single Institutional Cohort Study
Introduction: Neoadjuvant chemoradiation and Total Mesorectal Excision (TME) have shown pathological complete response (pCR) rates of 15-27%. The pCR is a significant predictor of ...
Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients
Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients
ABSTRACT
Background:
The efficacy of neoadjuvant therapy for rectal cancer has not been assessed.
Objective:
...
Complete Response Evaluation of Locally Advanced Rectal Cancer to
Neoadjuvant Chemoradiotherapy Using Textural Features Obtained from
T2 Weighted Imaging and ADC Maps
Complete Response Evaluation of Locally Advanced Rectal Cancer to
Neoadjuvant Chemoradiotherapy Using Textural Features Obtained from
T2 Weighted Imaging and ADC Maps
Background:
The prediction of pathological responses for locally advanced rectal cancer
using magnetic resonance imaging (MRI) after neoadjuvant chemoradiotherapy (CRT) is a challe...
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer
Abstract
Background Chromosome 3q26 amplifications have been shown to represent a frequent alteration in various cancer entities including breast cancer. SEC62 - a 3...

